• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHAT alert in real time by email
    New Drug Application (NDA): 215152
    Company: PHATHOM PHARMACEUTICALS, INC
    • Email

    Products on NDA 215152

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    VOQUEZNA TRIPLE PAK AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN 500MG; 500MG; 20MG CAPSULE, CAPSULE, TABLET Prescription TBD TBD No

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 215152

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    05/03/2022 ORIG-1 Approval Type 1 - New Molecular Entity and Type 4 - New Combination PRIORITY Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215152s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/215152Orig1s000, 215153Orig1s000ltr.pdf

    Labels for NDA 215152

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    05/03/2022 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215152s000lbl.pdf

    Therapeutic Equivalents for NDA 215152

    VOQUEZNA TRIPLE PAK

    There are no Therapeutic Equivalents.

    Get the next $PHAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHAT

    DatePrice TargetRatingAnalyst
    2/14/2025$23.00Overweight
    Cantor Fitzgerald
    5/3/2024$24.00Buy
    Stifel
    1/5/2024$23.00 → $26.00Buy
    Needham
    8/9/2023$28.00Buy
    H.C. Wainwright
    5/11/2023In-line → Outperform
    Evercore ISI
    3/13/2023$21.00Buy
    Craig Hallum
    10/21/2022$16.00Buy
    Jefferies
    5/6/2022Outperform → In-line
    Evercore ISI
    More analyst ratings

    $PHAT
    SEC Filings

    See more
    • SEC Form 8-K filed by Phathom Pharmaceuticals Inc.

      8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

      6/16/25 8:05:54 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Phathom Pharmaceuticals Inc.

      8-K - Phathom Pharmaceuticals, Inc. (0001783183) (Filer)

      6/9/25 4:01:20 PM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Phathom Pharmaceuticals Inc.

      SCHEDULE 13G/A - Phathom Pharmaceuticals, Inc. (0001783183) (Subject)

      6/9/25 10:47:42 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Phathom Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Phathom Pharmaceuticals with a rating of Overweight and set a new price target of $23.00

      2/14/25 7:06:18 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Phathom Pharmaceuticals with a new price target

      Stifel initiated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $24.00

      5/3/24 7:37:39 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Phathom Pharmaceuticals with a new price target

      Needham reiterated coverage of Phathom Pharmaceuticals with a rating of Buy and set a new price target of $26.00 from $23.00 previously

      1/5/24 8:05:02 AM ET
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care